TiGenix The Latest Partner In Takeda Deal Frenzy
This article was originally published in PharmAsia News
Executive Summary
The latest in a non-stop succession of deals over the past few weeks for Takeda sees the Japanese major add a late-stage TiGenix asset to its GI care portfolio, with Europe to be the initial focus of the tie-up.
You may also be interested in...
Takeda Gets Serious About Cell Therapy With TiGenix Buy
Takeda will acquire its Belgian biotech partner, TiGenix, to strengthen its gastro-intestinal portfolio, bolster its regenerative medicines capacity and grow its US specialty care presence.
New Crohn’s Indication Puts Janssen’s Stelara On Equal Ground With Anti-TNFs
J&J’s Janssen Biotech subsidiary won FDA approval for the IL-12/IL-23 inhibitor Stelara to treat Crohn’s disease, giving it a second-line position alongside anti-TNF therapies for patients in need of new options.
Japan Regulators Kept On Track Despite Pandemic
While it was not as affected as some other countries, Japan still had the pandemic to deal with and regulators responded while managing to keep up regular product review work, including several world-first approvals. Coronavirus vaccine roll-outs and the first general annual reimbursement price cut are on the cards for this year.
Need a specific report? 1000+ reports available
Buy Reports